Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.
Industry, Sector and Symbol:
- Trailing P/E Ratio: N/A
- P/E Growth: N/A
- Net Margins: -167,551.60%
- Return on Equity: -199.73%
- Return on Assets: -150.59%
Frequently Asked Questions for Aurinia Pharmaceuticals (TSE:ISA)
What is Aurinia Pharmaceuticals' stock symbol?
Aurinia Pharmaceuticals trades on the Tornton Stock Exchange (TSX) under the ticker symbol "ISA."
Who are some of Aurinia Pharmaceuticals' key competitors?
Some companies that are related to Aurinia Pharmaceuticals include Colliers International Group (CIG), Kirkland Lake Gold Ltd (NMI), Osisko Mining Corp (OBM), Royal Bank of Canada (RY), Toronto-Dominion Bank (TD), Bank of Nova Scotia (BNS), Enbridge (ENB), Canadian National Railway Company (CNR), Suncor Energy (SU), Bank of Montreal (BMO), TransCanada (TRP), BCE (BCE), Manulife Financial Corp. (MFC), Canadian Imperial Bank of Commerce (CM), Canadian Natural Resources Limited (CNQ), Thomson Reuters Corp (TRI), Great-West Lifeco (GWO) and Imperial Oil Ltd (IMO).
Who are Aurinia Pharmaceuticals' key executives?
Aurinia Pharmaceuticals' management team includes the folowing people:
- Richard M. Glickman LL.D., Executive Chairman of the Board, Chief Executive Officer
- Dennis Bourgeault, Chief Financial Officer, Corporate Secretary
- Michael R. Martin, Chief Operating Officer
- Neil Solomons M.D., Chief Marketing Officer
- Celia Economides, Associate Vice President, Corporate Communications & Patient Advocacy
- Robert B. Huizinga, Vice President - Clinical Affairs
- Lawrence D. Mandt, Vice President - Regulatory and Quality
- George M. Milne Jr., Ph.D., Director
- Lorin Jeffry Randall, Director
- Benjamin Rovinski Ph.D., Independent Director
How do I buy Aurinia Pharmaceuticals stock?
MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE ISA)MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shares of Aurinia Pharmaceuticals and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
Consensus Ratings for Aurinia Pharmaceuticals (TSE:ISA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Aurinia Pharmaceuticals (TSE:ISA)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Aurinia Pharmaceuticals (TSE:ISA)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Aurinia Pharmaceuticals (TSE:ISA)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Aurinia Pharmaceuticals (TSE:ISA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Aurinia Pharmaceuticals (TSE:ISA)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Aurinia Pharmaceuticals (TSE:ISA)
Latest Headlines for Aurinia Pharmaceuticals (TSE:ISA)
Aurinia Pharmaceuticals (ISA) Chart for Thursday, July, 20, 2017